NTLA-2001
ITL-2001-CL-301
Phase 3 mab active
Quick answer
NTLA-2001 for Transthyretin Amyloidosis (ATTR) With Cardiomyopathy is a Phase 3 program (mab) at REGENERON PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- REGENERON PHARMACEUTICALS, INC.
- Indication
- Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
- Phase
- Phase 3
- Modality
- mab
- Status
- active